New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats.
Earlier we indicated that neutrophilic invasion into cerebral parenchyma is an important step in rat cerebral ischemia-reperfusion injury and the production of chemotactic factors, cytokine-induced neutrophil chemoattractant (CINC) precede the neutrophilic invasion. The aim of the present study was to evaluate the role of CINC production and the therapeutic possibility of blocking CINC activity in the transient ischemic brain damage in rats. Focal transient ischemia was produced by intraluminal occlusion of the right middle cerebral artery for 60 min. An enzyme immunoassay was used to measure the brain concentration of CINC and myeloperoxidase activity in ischemic areas was measured as a marker of neutrophilic accumulation. An immunohistochemical staining technique was used to detect the immunopositive cells for anti-CINC antibody. Further, application of anti-CINC antibody or anti-neutrophil antibody to rats was used to evaluate the role of CINC production. In ischemic areas, CINC production was detected and peaked 12 h after reperfusion, which followed 60 min of ischemia. Intraperitoneal injection of anti-neutrophil antibody 24 h before and immediately after reperfusion significantly reduced the brain water content and partially reduced the CINC production in ischemic areas. Further, immunohistochemical staining showed that anti-CINC antibody was found on the endothelial surface of venules and on parts of neutrophils that had invaded the ischemic area 6 to 24 h after reperfusion. Also, treatment with anti-CINC antibody reduced ischemic edema formation 24 h after reperfusion and the size of infarction areas 7 days after reperfusion. It thus appears that CINC, mainly produced by endothelium activated by factors released from neutrophils, plays an important role in ischemic brain damage. Furthermore, the blocking of CINC activity with antibody suggests an immuno-therapeutic approach to the treatment of stroke patients.
Yamasaki
Y
Y
Hanno Research Center, Taiho Pharmaceutical Co. Ltd., Hanno City, Saitama, Japan.
Matsuo
Y
Y
Zagorski
J
J
Matsuura
N
N
Onodera
H
H
Itoyama
Y
Y
Kogure
K
K
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D001921:Brain / Q000201:enzymology / Q000473:pathology; D001925:Brain Damage, Chronic / Q000517:prevention & control*; D001929:Brain Edema / Q000209:etiology; D019743:Chemokines, CXC; D002630:Chemotactic Factors / Q000276:immunology* / Q000378:metabolism; D006133:Growth Substances / Q000276:immunology* / Q000378:metabolism; D007150:Immunohistochemistry; D007167:Immunotherapy; D036341:Intercellular Signaling Peptides and Proteins; D002546:Ischemic Attack, Transient / Q000150:complications* / Q000473:pathology / Q000628:therapy*; D008297:Male; D009474:Neurons / Q000473:pathology; D009504:Neutrophils / Q000276:immunology; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D015424:Reperfusion
D000906:Antibodies; D019743:Chemokines, CXC; D002630:Chemotactic Factors; D006133:Growth Substances; D036341:Intercellular Signaling Peptides and Proteins; D009195:Peroxidase